GANX - EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease | Benzinga
Gain Therapeutics Inc (NASDAQ:GANX) announces the presentation of a poster at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD 2024) related to the mechanism of action of the company’s lead compound, GT-02287.
The poster demonstrates how GT-02287, through its interaction with glucocerebrosidase (GCase) in the endoplasmic reticulum (ER), aids in correct GCase folding, preventing ER retention, ER stress and ER-associated degradation of mutated GCase enzyme.
GCase is consequently able to travel to the lysosome, resulting in enhanced lysosomal activity and efficient processing of the GCase substrate glucosylceramide.
An increase in GCase substrate in the lysosome was previously shown to ...